Foresight Biotherapeutics Announces Presentation at the 2010 Association for Research in Vision and Ophthalmology

NEW YORK--(Business Wire)--
Foresight Biotherapeutics, Inc. today announced data from a pre-clinical study
will be presented at the 2010 annual meeting of the Association for Research in
Vision and Ophthalmology (ARVO) being held in Ft. Lauderdale, Florida. The study
was designed to assess the safety and efficacy of the topical administration of
FST-100 in a widely accepted rabbit model of adenoviral conjunctivitis. FST-100
is the company`s lead product for the treatment of adenoviral conjunctivitis.
The results demonstrated a statistically significant effect in both clinical
cure and adenoviral eradication. The work was conducted at the Louisiana State
University (LSU) Health Sciences Center, LSU Eye Center in New Orleans,
Louisiana by Professor James M. Hill and colleagues. Detailed data are being
presented at a poster discussion session on Wednesday, May 5th at
8:30am-10:15am.

The study supports the potential for our product in the lead indication of
adenoviral conjunctivitis. Adenoviral conjunctivitis or "pink eye" is one of the
most common eye infections worldwide. It is highly contagious and is a frequent
cause of epidemics. There is currently no drug approved for the treatment of
adenoviral conjunctivitis.

About Foresight Biotherapeutics, Inc.

Foresight Biotherapeutics is a drug development company focused on diseases of
the eye and ear. The company`s website is: www.foresightbiotherapeutics.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of
Foresight relating to matters that are not historical facts (including without
limitation those regarding the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Foresight`s product candidates are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that future
research will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or abroad, the
ability of Foresight and/or its partners to develop, manufacture and
commercialize, Foresight`s ability to fund such efforts with or without
partners, and other risks.

Foresight Biotherapeutics
Investor Relations, 646-747-9100
admin@foresightbio.com

Copyright Business Wire 2010